Mohammad Rashid Siddiqui1, Campbell Grant2, Thomas Sanford1, Piyush K Agarwal3. 1. Bladder Cancer Section, Urologic Oncology Branch, National Cancer Institute, NIH, Bathesda, MD. 2. Department of Urology, George Washington University Medical Center, Washington, D.C. 3. Bladder Cancer Section, Urologic Oncology Branch, National Cancer Institute, NIH, Bathesda, MD. Electronic address: piyush.agarwal@nih.gov.
Abstract
BACKGROUND: The treatment options for non-muscle invasive bladder cancer (NMIBC) remain limited. Bacillus Calmette-Guerin (BCG) was the last major breakthrough in bladder cancer therapy almost 4 decades ago. There have been improvements in the understanding of immune therapies and cancer biology, leading to the development of novel agents. This has led to many clinical trials that are currently underway to find the next generation of therapies for NMIBC. METHOD: We reviewed clinicaltrials.org and pubmed.gov to find the recently completed and ongoing clinical trials in NIMBC. Included in this review are clinical trials that are currently active and trials that were completed in and after 2014. RESULT: Many trials with BCG-naive and BCG-unresponsive/recurrent/refractory/failure patients with NMIBC are either currently underway or have been recently completed. A wide variety of novel therapeutic agents are being investigated that range from cytotoxic agents to immunomodulatory agents to targeted molecular therapies. Other approaches include cancer vaccines, gene therapies, and chemoradiation potentiation agents. Novel drug-delivery methods are also being tested. CONCLUSION: This comprehensive update of current trials provides researchers an overview of the current clinical trial landscape for patients with NMIBC. Published by Elsevier Inc.
BACKGROUND: The treatment options for non-muscle invasive bladder cancer (NMIBC) remain limited. Bacillus Calmette-Guerin (BCG) was the last major breakthrough in bladder cancer therapy almost 4 decades ago. There have been improvements in the understanding of immune therapies and cancer biology, leading to the development of novel agents. This has led to many clinical trials that are currently underway to find the next generation of therapies for NMIBC. METHOD: We reviewed clinicaltrials.org and pubmed.gov to find the recently completed and ongoing clinical trials in NIMBC. Included in this review are clinical trials that are currently active and trials that were completed in and after 2014. RESULT: Many trials with BCG-naive and BCG-unresponsive/recurrent/refractory/failurepatients with NMIBC are either currently underway or have been recently completed. A wide variety of novel therapeutic agents are being investigated that range from cytotoxic agents to immunomodulatory agents to targeted molecular therapies. Other approaches include cancer vaccines, gene therapies, and chemoradiation potentiation agents. Novel drug-delivery methods are also being tested. CONCLUSION: This comprehensive update of current trials provides researchers an overview of the current clinical trial landscape for patients with NMIBC. Published by Elsevier Inc.
Authors: Nicholas M Donin; Karim Chamie; Andrew T Lenis; Allan J Pantuck; Madhu Reddy; Dana Kivlin; Johanna Holldack; Rafaella Pozzi; Gil Hakim; Lawrence I Karsh; Donald L Lamm; Laurence H Belkoff; Arie S Belldegrun; Stuart Holden; Neal Shore Journal: Urol Oncol Date: 2016-10-26 Impact factor: 3.498
Authors: Catherine M Seager; Anna M Puzio-Kuter; Trushar Patel; Shalini Jain; Carlos Cordon-Cardo; James Mc Kiernan; Cory Abate-Shen Journal: Cancer Prev Res (Phila) Date: 2009-12-01
Authors: Jonathan E Rosenberg; Jean Hoffman-Censits; Tom Powles; Michiel S van der Heijden; Arjun V Balar; Andrea Necchi; Nancy Dawson; Peter H O'Donnell; Ani Balmanoukian; Yohann Loriot; Sandy Srinivas; Margitta M Retz; Petros Grivas; Richard W Joseph; Matthew D Galsky; Mark T Fleming; Daniel P Petrylak; Jose Luis Perez-Gracia; Howard A Burris; Daniel Castellano; Christina Canil; Joaquim Bellmunt; Dean Bajorin; Dorothee Nickles; Richard Bourgon; Garrett M Frampton; Na Cui; Sanjeev Mariathasan; Oyewale Abidoye; Gregg D Fine; Robert Dreicer Journal: Lancet Date: 2016-03-04 Impact factor: 79.321
Authors: James M McKiernan; Dara D Holder; Rashed A Ghandour; LaMont J Barlow; Jennifer J Ahn; Max Kates; Gina M Badalato; Arindam Roychoudhury; G Joel Decastro; Mitchell C Benson Journal: J Urol Date: 2014-07-01 Impact factor: 7.450
Authors: Evan Gomes-Giacoia; Makito Miyake; Steve Goodison; Aravindhan Sriharan; Ge Zhang; Lijing You; Jack O Egan; Peter R Rhode; Alexander S Parker; Karl X Chai; Hing C Wong; Charles J Rosser Journal: PLoS One Date: 2014-06-04 Impact factor: 3.240
Authors: Jonathan J Duplisea; Sharada Mokkapati; Devin Plote; Kimberly S Schluns; David J McConkey; Seppo Yla-Herttuala; Nigel R Parker; Colin P Dinney Journal: World J Urol Date: 2018-11-11 Impact factor: 4.226
Authors: Sharada Mokkapati; Vikram M Narayan; Ganiraju C Manyam; Amy H Lim; Jonathan J Duplisea; Andrea Kokorovic; Tanner S Miest; Anirban P Mitra; Devin Plote; Selvalakshmi Selvaraj Anand; Michael J Metcalfe; Kenneth Dunner; Burles A Johnson; Bogdan A Czerniak; Tiina Nieminen; Tommi Heikura; Seppo Yla-Herttuala; Nigel R Parker; Kimberley S Schluns; David J McConkey; Colin P Dinney Journal: Mol Ther Oncolytics Date: 2022-06-10 Impact factor: 6.311